Vildagliptin is a cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Vildagliptin’s cyano moiety undergoes hydrolysis and this inactive metabolite is excreted mainly via the urine. It is grouped under the following drug class(es): DPP-4 inhibitors and Hypoglycemics. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Equa, Galvus, Xiliarx and Jalra. Its PubChem CID is 6918537.
Vildagliptin
| CAS No | 274901-16-5 |
|---|---|
| Molecular Formula | C17H25N3O2 |
| Molecular Weight | 303.4 g/mol |
| Synonyms | (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Vildagliptin is a cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Vildagliptin's cyano moiety undergoes hydrolysis and this inactive metabolite is excreted mainly via the urine.
The listed CAS number is 274901-16-5.
The listed molecular formula is C17H25N3O2.
The listed molecular weight is 303.4 g/mol.
(2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile.
The source lists Equa, Galvus, Xiliarx and Jalra.